Human alveolar echinococcosis - global, regional and national annual incidence and prevalence rates.

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection Pub Date : 2025-03-05 DOI:10.1016/j.cmi.2025.01.034

Britta Lundström-Stadelmann, Ali Rostami, Caroline F Frey, Paul R Torgerson, Seyed Mohammad Riahi, Kimia Bagheri, Marc Kaethner, Anja Lachenmayer, Guido Beldi, Robin B Gasser, Andrew Hemphill

{"title":"Human alveolar echinococcosis - global, regional and national annual incidence and prevalence rates.","authors":"Britta Lundström-Stadelmann, Ali Rostami, Caroline F Frey, Paul R Torgerson, Seyed Mohammad Riahi, Kimia Bagheri, Marc Kaethner, Anja Lachenmayer, Guido Beldi, Robin B Gasser, Andrew Hemphill","doi":"10.1016/j.cmi.2025.01.034","DOIUrl":null,"url":null,"abstract":"Background: Alveolar echinococcosis (AE) of humans is a disease caused by the larval (metacestode) stage of the 'fox tapeworm' Echinococcus multilocularis. AE primarily affects the liver and, like a cancer, can spread to surrounding or distant organs. Its slow progression and resemblance to malignant tumours emphasise the critical importance of early detection and intervention, as there is no highly effective vaccine against AE. Although recognized as a \"neglected disease\", there has been no recent, comprehensive review of the distribution, incidence and prevalence of AE in humans around the world.Objective: To estimate the global, regional and national annual incidence rates (AIRs) and prevalences of human AE in endemic countries.Sources: Incidence and prevalence data were obtained from published articles from 1980 to February 2024, accessible via public databases.Content: This article provides a brief background on E. multilocularis, its biology and impact; reviews the geographic distribution and incidence of AE; and gives a perspective on the prevention and control of this neglected disease in humans.Implications: The AE burden in humans is substantial and emphasises the need for enhanced public awareness, surveillance, prevention and control, particularly in under-resourced communities to mitigate the health, economic and psychological impact of AE. Britta Lundström-Stadelmann,Clin Microbiol Infect 2024; XX:XXX© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiologyand Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2025.01.034","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alveolar echinococcosis (AE) of humans is a disease caused by the larval (metacestode) stage of the 'fox tapeworm' Echinococcus multilocularis. AE primarily affects the liver and, like a cancer, can spread to surrounding or distant organs. Its slow progression and resemblance to malignant tumours emphasise the critical importance of early detection and intervention, as there is no highly effective vaccine against AE. Although recognized as a "neglected disease", there has been no recent, comprehensive review of the distribution, incidence and prevalence of AE in humans around the world.

Objective: To estimate the global, regional and national annual incidence rates (AIRs) and prevalences of human AE in endemic countries.

Sources: Incidence and prevalence data were obtained from published articles from 1980 to February 2024, accessible via public databases.

Content: This article provides a brief background on E. multilocularis, its biology and impact; reviews the geographic distribution and incidence of AE; and gives a perspective on the prevention and control of this neglected disease in humans.

Implications: The AE burden in humans is substantial and emphasises the need for enhanced public awareness, surveillance, prevention and control, particularly in under-resourced communities to mitigate the health, economic and psychological impact of AE. Britta Lundström-Stadelmann^,Clin Microbiol Infect 2024; XX:XXX© 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiologyand Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Microbiology and Infection 医学-传染病学

CiteScore

25.30

自引率

2.10%

发文量

441

审稿时长

2-4 weeks

期刊介绍： Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.